Christophe commented, “We have experienced a period of exponential growth which saw us thrust us into the position of a global business. To meet this challenge we have carried out a complete overhaul of our operating systems, the strengthening of our management team and a renewed focus on the therapy areas where we can add most value – cardiovascular, metabolic (diabetes and obesity), bone, respiratory and CNS (dementia and pain). We have now finalised the new structure and have put in place a management team – outlined below - prepared for the continued growth in the years ahead.”
The Synexus Global Executive Team comprises; Dr Christophe Berthoux, Chief Executive; Jane Restorick, Chief Operating Officer; Chris Hannigan, Commercial Director; Paul Chambers, Chief Financial Officer; Dr Glynis Neagle, Chief Medical Officer and Wendy Ingham Group Human Resources Director.
Supporting them is the Global Management Team of; Alison Martin, VP International Projects; Tony Healy Group IT Director and Janet Jones, who recently joined from CRO ICON, VP Access to Patients.
A new regional structure - reporting to COO Jane Restorick - is headed by regional directors who are responsible for the day to day running of the dedicated research centres in their territories, new business and profitability.
Klaus- Dieter Albrecht, who has just been appointed Managing Director of Synexus Germany, is responsible for the management of the seven Synexus dedicated clinical trial centres in Germany. Dr Sanet Aspinall managing director of Synexus South Africa is responsible for the two centres in South Africa. Dr Radoslaw Janiak is Managing Director of Synexus Central and Eastern Europe with responsibility for eight centres in Poland, Bulgaria, Ukraine, and Hungary. Angela Harnick is operational director of the UK responsible for seven centres across England, Wales and Scotland.
Speaking of the changes Dr Christophe Berthoux CEO of Synexus said: “Our management team is composed of some of the most experienced people in the industry. They are delivering to our clients in pharma and CROs the numbers of patients they need and excellent quality data from all of our 25 dedicated research centres across the world.”
“Rather than being a totally centralised organisation we have a management structure that provides comprehensive support but also recognises and enables the regional teams to run their own operations. In particular with regards patient acquisition as it is vital that these activities are in line with the health systems in each country. This blend of local initiatives operating within a very tight regulatory framework allows the company to move forward much more rapidly.”
For more information about Synexus visit www.synexus.com
